Bupivacaine Injection Market Size & Outlook, 2025-2033

Bupivacaine Injection Market Size

The global bupivacaine injection market size was valued at USD 1.19 billion in 2024, and it is estimated to grow from USD 1.27 billion by 2025 to USD 2.17 billion by 2033, growing at a CAGR of 5.6% during the forecast period (2025–2033). Factors such as High Prevalence of Malocclusion and Growing Opportunities in Anesthetic Drug Approvals, significantly drives the bupivacaine injection market demand by 2033.

Bupivacaine injection acts as local or regional anesthesia or analgesia for various surgical, diagnostic, therapeutic, and obstetrical treatments. They are used to numb a specific part of your body before, during, or after surgery, other treatments, delivery, or dental work. It is also used to numb your shoulder for up to 72 hours following surgery. It induces numbness and pain relief by inhibiting impulses at nerve terminals, and it does not result in a loss of consciousness.

The bupivacaine injection market is divided into type, end-user, and regions. The report's extensive segmentation provides a complete study of the minor section of the global market for bupivacaine injection.

To get more insights about this report Download Free Sample Report

Bupivacaine Injection Market Drivers

The High Prevalence of Malocclusion to Surge the Demand in the Market

People are living longer lives across the world. According to the World Health Organization (WHO), the world's population of people aged 60 and more is predicted to reach 2 billion by 2050, up from 900 million in 2015. According to figures provided by the Center for Strategic and International Studies China Power Project, China's senior population aged 65 and above was 9.5% in 2015 and the figure is expected to climb to 27.5% by 2050.

Further, as per the World Bank data, India's elderly population of 65 and above was reported to be 6.3779% of the overall population in 2019. About 80% of all older people are predicted to reside in low- and middle-income nations. Additionally, according to United Nations figures, one in every four persons in North America and Europe maybe 65 or older. In 2018, people aged 65 and more outnumbered children under five globally.

Further, chronic illnesses become more common as the population ages, increasing procedures. The main factors contributing to increasing demand are widespread use in postoperative pain and the growing number of older people across the globe. This is predicted to contribute to market growth over the evaluation period significantly.

Market Restraining Factors

The Side Effects of Bupivacaine Injection to Hamper the Market Growth

The bupivacaine injection has a few side effects, and these can potentially be lethal if not administered with caution and attention. Although local anesthetics affect cardiac and CNS (central nervous system) function, bupivacaine injection can cause an atrioventricular block, ventricular arrhythmias, and cardiac arrest. When administered intravenously into dangerous blood concentrations, these adverse effects can be fatal. As a result, regular examination and attention are necessary here. These bupivacaine injectables' negative impacts are predicted to stifle market expansion.

Bupivacaine Injection Market Opportunities

Growing Opportunities in Anesthetic Drug Approvals

Pacira Pharmaceuticals Inc. is a rapidly expanding pharmaceutical firm known for its drug Exparel. LGM Pharma, Pfizer, Sagent Pharmaceuticals Inc., and BOC Sciences are the key players in the global market.

PaciraBioSciences Inc.'s supplemental new drug application (sNDA) for the extended use of its Exparel (Bupivacaine Liposome Injectable Suspension) in pediatric patients was accepted by the US Food and Drug Administration (FDA) in March 2021. Such new anesthetic medication approvals, such as bupivacaine, are projected to provide substantial market growth prospects.

Regional Insights

Significant Growth in Asia-Pacific and Europe

The global bupivacaine injection market share has been segmented into four regions: the Americas, Europe, Asia-Pacific, the Middle East and Africa. The market is divided into geographical categories to allow for a more in-depth examination of the industry from a regional standpoint. The American market maintained a considerable market share during the projected period and is predicted to increase rapidly. 

Furthermore, the United States is expected to create more money at the national level. The expanding aging population, increasing operations with chronic illnesses, and enhanced anesthetic technologies drive the bupivacaine injection market in the United States. The key companies are attempting to innovate medications, driving market growth. 

Moreover, the federal government's initiatives for disease awareness, favorable reimbursement policies, increased demand for better patient care, technological advancements, well-established medical infrastructure, an increased number of older people are conclusively driving market growth in North America.

The European region is further subdivided into the United Kingdom, Germany, France, Spain, Italy, and the rest of Europe. Europe has the second-largest share and is predicted to increase reasonably throughout the projection period. The increased use of local anesthetics in postoperative pain management is ascribed to advancements in surgical techniques, dental and cosmetic surgery, and the expanding use of local anesthetics in postoperative pain management.

Segmental Analysis

The 0.25% category is expected to increase significantly during the forecast period. Bupivacaine 0.25% w/v and 0.5% w/v injectable solutions are used to create local anesthesia by the peripheral nerve block, central neural block, and percutaneous infiltration for specialized usage in cases requiring sustained anesthesia. The sensory nerve block is more noticeable than the motor nerve block. Bupivacaine is mainly used to treat pain, such as labor discomfort.

The hospital segment is expected to develop significantly throughout the forecast period due to the rising demand for local anesthetic medications. Furthermore, the government and independent healthcare organizations have launched several local anesthetic medications, which are projected to support the market's segmental expansion. During the assessment period, the creation of hospital pharmacies in cardiology, neurology, and other disorders in established and emerging economies and an increase in the number of hospitals and an acceptable reimbursement environment would boost market expansion.

Impact of Covid-19

The coronavirus pandemic has devastated the worldwide healthcare system. The World Health Organization (WHO) classified respiratory illness COVID-19 as a global pandemic in March 2020. Social distancing, government measures of lockdown, self-isolation, and the lack of appropriate treatment are the factors that have drastically impacted the healthcare system. It brought about dynamic changes in product demand, capacity, and the healthcare context.

COVID-19 pandemic caused substantial disruptions in commodities demand across several end-use sectors, with global supply chains affected and the manufacturer's hierarchy altered. A lack of demand resulted in an overstock problem in the worldwide medical device business. Movement restrictions directly influenced the market.

Further, all non-emergent surgical operations in clinics and hospitals were halted to minimize the rush of new cases and save resources for treating COVID-19 positive patients. All these changes in the healthcare industry have significantly influenced the production and demand for bupivacaine injection in the market. Nonetheless, due to its benefits and minimal risk of viral transmission, local anesthesia in treating SARS-CoV-2-infected patients is becoming more popular.

Research published in the European Archives of Oto-Rhino-Laryngology in 2020 found that topical oropharyngeal lignocaine therapy improved patient comfort during COVID-19 oropharyngeal sampling. Although it did not affect COVID-19 virus detection in the upper airway, the study indicated it might reduce viral inoculum sampling in COVID-19 suspects. The pandemic is likely to boost market products in general during the forecast period.

List of key players in Bupivacaine Injection Market

1. Pfizer Inc.
2. Fresenius Kabi AG
3. Baxter International Inc.
4. AstraZeneca Plc
5. Shanghai Harvest Pharmaceutical Co., Ltd
6. AuroMedics Pharma LLC
7. Areva
8. SteriMax Inc.
9. Zhaohui Pharmaceutical
10. Shandong Hualu Pharmaceutical
11. Aurobindo Pharma
12. Braun Melsungen AG
13. Sagent Pharmaceuticals
14. Pacira Pharmaceuticals, Inc.
15. Septodont

To get more findings about this report Download Market Share

Recent Developments

• March 2022 – Pfizer has acquired Arena Pharmaceuticals. The acquisition provides a novel, distinctive, and possibly best-in-class method to meeting the demands of a more significant number of patients suffering from immuno-inflammatory illnesses.
• March 2022 – Virpax Pharmaceuticals Expands AnQlarTM Development and Commercialization Rights Through Worldwide Licensing Agreement.